Blog
RSS FeedPosted by Michael Wonder on 22 Dec 2024
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
20 December 2024 - For the first time, NICE has recommended an innovative new treatment to help stop babies, children and ...
Posted by Michael Wonder on 18 Dec 2024
Ublituximab for the treatment of patients with relapsing multiple sclerosis
18 December 2024 - NICE has published final Evidence-based recommendations on the use of ublituximab (Briumvi) for the treatment of adults ...
Posted by Michael Wonder on 12 Dec 2024
Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced oesophageal squamous cell cancer
11 December 2024 - NICE is unable to make a recommendation on the use in the NHS of toripalimab (Loqtorzi) in ...
Posted by Michael Wonder on 12 Dec 2024
Elranatamab for treating relapsed and refractory multiple myeloma after three or more treatments (final guidance)
11 December 2024 - NICE has published final evidence-based recommendations on the use of elranatamab (Elrexfio) for the treatment of ...
Posted by Michael Wonder on 10 Dec 2024
New price deal paves way for NICE approval of treatment for rare genetic condition
10 December 2024 - A new treatment for Duchenne muscular dystrophy is set to be available to around 1,700 people in ...
Posted by Michael Wonder on 06 Dec 2024
Molnupiravir for the treatment of patients with COVID-19 infection
26 November 2024 - NICE has published further draft guidance on the use of molnupiravir (Lagevrio) in the NHS in ...
Posted by Michael Wonder on 04 Dec 2024
Fedratinib dihydrochloride monohydrate for the treatment of adults with disease-related splenomegaly or symptoms in myelofibrosis
20 November 2024 - NICE has published final evidence-based recommendations on the use of fedratinib dihydrochloride monohydrate (Inrebic) for the ...
Posted by Michael Wonder on 14 Nov 2024
Elafibranor for the treatment of patients with primary biliary cholangitis
14 November 2024 - NICE has published final evidence-based recommendations on the use of elafibranor (Iqirvo) for the treatment of ...
Posted by Michael Wonder on 13 Nov 2024
Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...
Posted by Michael Wonder on 06 Nov 2024
Fenfluramine hydrochloride for the treatment of patients 2 years of age and older with seizures associated with Lennox–Gastaut syndrome
5 November 2024 - Following an appeal, NICE has published further draft guidance on the use of using fenfluramine hydrochloride ...
Posted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...
Posted by Michael Wonder on 24 Oct 2024
Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...
Posted by Michael Wonder on 23 Oct 2024
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
23 October 2024 - More evidence is needed on the clinical and cost effectiveness of donanemab, a new treatment for mild ...
Posted by Michael Wonder on 23 Oct 2024
Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (final guidance)
23 October 2024 - NICE has published final evidence-based recommendations on the use of danicopan (Voydeya) in combination with ravulizumab ...
Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...